Clinical Report: Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy

Overview

This multicenter case series identifies immune effector cell-associated enterocolitis (IEC-EC) as a significant complication following BCMA-targeted CAR T-cell therapy in multiple myeloma. The study highlights the clinical characteristics, treatment responses, and outcomes of affected patients.

Background

Chimeric antigen receptor T-cell therapy targeting B cell maturation antigen (BCMA) has emerged as an effective treatment for relapsed multiple myeloma. However, immune-mediated toxicities, particularly IEC-EC, pose significant challenges in patient management and understanding the long-term effects of this therapy. Recognizing and addressing these complications is crucial for optimizing treatment outcomes.

Data Highlights

Key Findings

• IEC-EC occurred in 4.3% of patients treated with ciltacabtagene autoleucel.
• Median onset of diarrhea was 81 days post-CART infusion.
• 84% of patients experienced Grade 3 or higher diarrhea and/or colitis.
• Delayed neurotoxicity preceded diarrhea in 26% of patients.
• 37% of patients achieved complete resolution of symptoms by last follow-up.
• Overall mortality related to IEC-EC was 37%, with complications leading to death in several cases.

Clinical Implications

Healthcare professionals should be vigilant for signs of IEC-EC in patients undergoing BCMA-targeted CAR T-cell therapy, particularly those presenting with diarrhea after treatment. Early recognition and management of this condition may improve patient outcomes and reduce morbidity associated with this therapy.

Conclusion

IEC-EC represents a late-onset, high-morbidity complication of BCMA-directed CAR T-cell therapy in multiple myeloma. Understanding its clinical course and management is essential for improving patient care in this setting.

References

1. Fortuna et al., Blood Cancer Journal, 2024 -- Enterocolitis Linked to Immune Effector Cell Therapy in Patients with Multiple Myeloma Following CAR-T Treatment
2. Blood Cancer Journal, 2024 -- Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?
3. Blood Cancer Journal, 2024 -- Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
4. FDA Approval Summary, PubMed, 2024 -- Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma
5. Blood Cancer Journal — Development of chronic inflammatory demyelinating polyneuropathy (CIDP) following cilta-cel treatment
6. FDA approves labeling changes that include a Boxed Warning for Immune Effector Cell-associated Enterocolitis
7. FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma - PubMed
8. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma | Blood Cancer Journal